What SURMOUNT-1 Actually Changes in Clinical Practice

At a glance

| Parameter | Detail | |-----------|--------| | N | 2,539 adults with BMI ≥30 (or ≥27 with comorbidity), without diabetes | | Intervention | Tirzepatide 5 mg, 10 mg, or 15 mg subcutaneous once weekly | | Comparator | Placebo (all arms included lifestyle intervention) | | Duration | 72 weeks (20-week dose escalation + 52-week maintenance) | | Primary endpoint | Percent change in body weight from baseline | | Key result | −15.0% (5 mg), −19.5% (10 mg), −20.9% (15 mg) vs −3.1% placebo |

The pre-SURMOUNT prescribing reality

Before this trial reported in June 2022, most obesity-medicine clinicians considered pharmacotherapy a tool for incremental weight loss in the 5-10% range. Semaglutide 2.4 mg (Wegovy) had already shifted the ceiling upward with its STEP 1 result of 14.9%, but tirzepatide's dual GIP/GLP-1 mechanism was unproven in a non-diabetic obesity population.

Liraglutide (Saxenda) remained the most commonly prescribed injectable, partly due to familiarity and partly because Wegovy supply constraints limited access throughout 2021-2022. The clinical calculus was straightforward: most drugs got patients 5-8% loss, bariatric surgery got them 25-35%, and nothing reliably occupied the space between.

SURMOUNT-1 collapsed that gap. A 20.9% mean reduction at the highest dose placed pharmacotherapy squarely in the range historically reserved for sleeve gastrectomy, which meta-analyses report at 20-25% total body weight loss at 1-2 years.

Methodology details that matter for translation

Population characteristics that limit or extend generalizability

The trial enrolled adults aged 18+ with BMI ≥30, or ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). Mean baseline BMI was 38.0 kg/m², mean age 44.9 years. The trial excluded patients with type 2 diabetes, prior bariatric surgery, or recent cardiovascular events within 60 days.

The exclusion of diabetes matters. Patients with type 2 diabetes typically lose less weight on GLP-1 receptor agonists (a pattern confirmed in the SURMOUNT-2 diabetes trial, where mean loss was 14.7% at 15 mg). Clinicians should not promise SURMOUNT-1-level results to patients with established diabetes.

Racial composition was 70.5% White, 15.7% Hispanic/Latino, 5.8% Black. Representation was somewhat narrow for a condition that disproportionately affects Black and Hispanic populations in the US.

The dose-escalation protocol

All three tirzepatide arms started at 2.5 mg weekly and escalated every 4 weeks. The 5 mg arm reached target by week 4, the 10 mg arm by week 12, and the 15 mg arm by week 20. This 20-week ramp means the maintenance period at full dose was only 52 weeks for the highest arm.

This is operationally important. Clinicians who expect to see the trial's full weight-loss trajectory must commit to the full escalation and sustain treatment for a year-plus beyond it. Stopping at 10 mg because the patient "feels good enough" at month 4 means forgoing a meaningful incremental benefit (the 10 mg to 15 mg difference was 1.4 percentage points of body weight, which translates to about 1.5 kg additional loss for a 105 kg patient).

Estimand structure

SURMOUNT-1 reported two estimands. The "treatment-regimen" estimand (intention-to-treat, including data after discontinuation) showed −15.0%, −19.5%, and −20.9% for the 5, 10, and 15 mg doses respectively versus −3.1% for placebo. The "efficacy" estimand (on-treatment data only) showed slightly higher values: −16.1%, −21.4%, −22.5%.

The gap between these estimands tells us discontinuation bias is modest. Roughly 14-19% of patients across active arms discontinued treatment, but many still lost weight relative to baseline, suggesting the drug effect partly persists in the weeks after stopping (though long-term regain is likely without continued therapy).

What guidelines actually changed

American Gastroenterological Association (2022)

The AGA's Clinical Practice Guideline on Pharmacological Interventions for Adults with Obesity published in October 2022 included tirzepatide in its strong recommendation tier. The guideline explicitly acknowledged that newer agents achieve weight losses previously attainable only with surgery and recommended shared decision-making that includes pharmacotherapy as a first-line option alongside lifestyle modification, not merely a supplement to it.

Endocrine Society (2024 update)

The Endocrine Society guideline released in 2024 elevated GLP-1 receptor agonists and dual agonists to preferred pharmacotherapy for adults with BMI ≥30. The committee specifically cited SURMOUNT-1 efficacy data in recommending tirzepatide when ≥15% weight loss is the clinical target.

FDA labeling and the Zepbound approval

The FDA approved tirzepatide for chronic weight management as Zepbound in November 2023. The label specifies the 72-week trial results and includes all three dose tiers, giving clinicians formal latitude to titrate to patient tolerance. The approval was based on SURMOUNT-1 and SURMOUNT-2 together, but SURMOUNT-1 provided the non-diabetic efficacy anchor.

What this changes at the prescription pad

The "try lifestyle first" default is weaker

For patients with BMI ≥35 (roughly 60% of the SURMOUNT-1 cohort), the magnitude of pharmacotherapy benefit now makes "three months of diet and exercise before we consider medication" harder to justify clinically. Multiple societies now recommend concurrent initiation of lifestyle and pharmacotherapy for patients likely to benefit.

Dose conversations require specificity

The 5 mg dose produced 15% loss. The 15 mg dose produced 20.9%. This is not a trivial spread. Clinicians should discuss with patients:

• Whether the additional GI side effects at higher doses (nausea occurred in 24.6% at 5 mg vs 33.3% at 15 mg) are tolerable
• Whether the additional 5-6 percentage points of weight loss are clinically meaningful for their specific comorbidity profile
• That time-to-effect is longer at higher doses due to the escalation schedule

Cost-effectiveness framing shifted

At roughly $1,000/month out-of-pocket without insurance, tirzepatide was initially viewed as cost-prohibitive for the magnitude of benefit. But when the benefit is 20% weight loss (not 5%), the cost-per-quality-adjusted-life-year calculation changes substantially. Several commercial payers expanded coverage for tirzepatide in 2024 specifically because the NNT to achieve clinically significant (≥10%) weight loss was approximately 1.3 for the 15 mg dose, meaning nearly every patient treated achieves a clinically significant outcome.

Results beyond the headline

Body composition data

SURMOUNT-1 substudy data showed roughly two-thirds of weight lost was fat mass. While some lean mass loss occurred (the expected ratio for caloric-deficit weight loss), the proportion of fat loss was consistent with or slightly better than what bariatric surgery achieves.

Cardiometabolic improvements

| Marker | Tirzepatide 15 mg | Placebo | |--------|-------------------|---------| | Waist circumference | −19.4 cm | −3.4 cm | | Systolic BP | −7.2 mmHg | −1.0 mmHg | | Triglycerides | −36.3% | −5.7% | | HDL cholesterol | +8.0% | +1.8% | | Fasting insulin | −55.0% | −4.7% |

These secondary outcomes matter because they predict downstream reduction in cardiovascular events, type 2 diabetes incidence, and hepatic steatosis progression. The insulin reduction of 55% in a non-diabetic population is particularly striking and suggests tirzepatide modifies the metabolic trajectory that precedes diabetes diagnosis.

Safety signals

The most common adverse events were gastrointestinal: nausea (24-33%), diarrhea (18-21%), constipation (11-17%), and vomiting (9-12%). Most GI events were mild-to-moderate and concentrated during escalation. Discontinuation due to adverse events was 4.3-7.1% across active arms versus 2.6% for placebo.

No signal for pancreatitis, medullary thyroid carcinoma, or major adverse cardiovascular events emerged. Gallbladder-related events occurred in 0.4-1.5% of tirzepatide patients versus 0.4% placebo, consistent with rapid weight loss from any cause.

What SURMOUNT-1 does not tell clinicians

Duration of therapy. The trial lasted 72 weeks. Weight regain after GLP-1 RA discontinuation is well-documented (STEP 1 extension data showed two-thirds of weight regain within a year of stopping). SURMOUNT-1 provides no data on outcomes beyond 72 weeks, and the clinical implication is that most patients will require indefinite treatment.

Head-to-head vs semaglutide. SURMOUNT-1 had no active comparator. Cross-trial comparisons with STEP 1 (semaglutide 2.4 mg, 14.9% loss at 68 weeks) are suggestive but confounded by different baseline BMIs, different trial durations, and different population compositions. The SURMOUNT-5 trial is expected to provide direct comparison data.

Older adults. Mean age was 44.9 years. Patients over 65 comprised a small fraction of the cohort. The safety and efficacy profile in older adults, where sarcopenia from lean-mass loss is a greater concern, cannot be extrapolated from these data.

Non-White populations at scale. With only 5.8% Black enrollment, the generalizability to populations with the highest obesity prevalence in the US remains incompletely characterized.

The practical bottom line for prescribers

SURMOUNT-1 made three things concrete that were previously theoretical:

1. Pharmacotherapy can reliably produce surgical-magnitude weight loss in most patients who tolerate the full dose.
2. The dose-response curve is clinically meaningful (5 mg to 15 mg represents 6 percentage points of additional body weight lost).
3. The GI tolerability profile, while common, is manageable enough that 80%+ of patients completed 72 weeks of treatment.

For the clinician writing a prescription today, the trial implies: start tirzepatide when the patient needs ≥15% weight loss to modify their disease trajectory, commit to full escalation over 20 weeks, plan for indefinite maintenance therapy, and set patient expectations that maximum effect occurs at 9-12 months on the target dose, not at 3 months.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PubMed
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed
3. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. PubMed
4. Zepbound (tirzepatide) prescribing information. Eli Lilly and Company. November 2023. FDA Label
5. Grunvald E, Shah R, Engel SS, et al. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults with Obesity. Gastroenterology. 2022;163(5):1198-1225. PubMed
6. Demssie YN, et al. Endocrine Society Clinical Practice Guideline on Pharmacological Management of Obesity. J Clin Endocrinol Metab. 2024. PubMed